Replies to post #212961 on Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

A more careful reading reveals the following:

1) IV verses B-OM swish and spit.
2) long and frequent visits to administer IV verses B-OM swish and spit at home.
3) the regimen adds about $1500 per visit (could be up to $2400) to cost of onco therapy, for how many visits?
4) May not be covered by most insurers.
5) focus in report was on <60 Gy verses >60 Gy for B-OM with <55 Gy thrown out.

[sox040713]

B-OM's result is better with stricter criteria IMO.

In addition they reported "in the overall incidence of SOM through 60 Gy of radiation" We reported "cumulative radiation dose criteria of at least 55 Gy—the minimum treatment threshold for inclusion in the efficacy population." So we made it more challenging for ourselves by using the lower number of 55GY.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137691726

Then there's oral rinse vs. IV. Good luck trying to get insurance to reimburse IV treatments for seven weeks when the alternative is an oral rinse.

BTW, what BP has partnered with Galera? I couldn't check because their website was down.